A NEW APPROACH TO THE TREATMENT OF TYPE 2 DIABETES MELLITUS WITH CORONARY HEART DISEASE

In modern clinical practice, type 2 diabetes mellitus therapy should be aimed not only at achieving glycemic control, but also at influencing other modified risk factors for the development of cardiovascular diseases, including hypertension, overweight, frequent hypoglycemia, etc. [4]. Empagliflozin is the first hypoglycemic drug for which a new indication has been approved for use as a means to reduce the risk of cardiovascular mortality in patients with type 2 diabetes mellitus and concomitant cardiovascular diseases.